임상 한눈에 보기

• 4건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 4건 · 완료/종료 0건
• Phase: Phase 3 · Phase 1, Phase 2 · Phase 2
• Status: Recruiting · Active, not recruiting
• 주요 endpoint: Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 · Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104 · Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104 · Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm · Mean change from baseline in Central Subfield Thickness (CST) over time through Weeks 52 and 104
• 등록 대상자(표본 합산): 약 1,247명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.